Literature DB >> 22650156

Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples.

Mark Reinwald1, Birgit Spiess, Werner J Heinz, Jörg J Vehreschild, Cornelia Lass-Flörl, Michael Kiehl, Beate Schultheis, Stefan W Krause, Hans-Heinrich Wolf, Hartmut Bertz, Georg Maschmeyer, Wolf-Karsten Hofmann, Dieter Buchheidt.   

Abstract

OBJECTIVES: Diagnosing invasive pulmonary aspergillosis (IPA) remains a challenge in patients with hematological malignancies. The clinical significance of testing bronchoalveolar lavage (BAL) samples both with polymerase chain reaction (PCR) and Aspergillus galactomannan ELISA (GM) is unclear, and the BAL cutoff for GM has not been clearly evaluated yet.
METHODS: Using a validated nested PCR assay and a GM ELISA, we prospectively examined BAL samples from 87 hematological patients at high risk of IPA. Of 76 (87%) evaluable patients, 29 patients had proven or probable disease.
RESULTS: The receiver operating characteristic (ROC) analysis of GM optical density (OD) cutoff levels yielded a BAL OD of 0.5 to be optimal. We identified 29 probable or proven cases based on this OD. Sensitivity and specificity for BAL GM were 0.79 (95% CI, 0.62-0.9) and 0.96 (95% CI, 0.86-0.99), respectively. For BAL PCR, sensitivity and specificity were 0.59 (95% CI, 0.41-0.75) and 0.87 (95% CI, 0.75-0.94), respectively. Combining BAL GM and PCR for diagnosis showed a sensitivity and specificity rate of 0.55 (95% CI, 0.38-0.72) and 1.0 (95% CI, 0.93-1.0), respectively, if positivity was defined by positive results for both tests. If either positive BAL GM or positive BAL PCR results defined test positivity, the sensitivity was 0.83 (95% CI, 0.65-0.92), and the specificity was 0.83 (95% CI, 0.70-0.91)
CONCLUSIONS: In terms of optimal sensitivity and specificity, a GM OD cutoff of 0.5 was determined for BAL samples. Positivity for both GM and Aspergillus PCR in BAL makes a pulmonary aspergillosis highly likely.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22650156     DOI: 10.1111/j.1600-0609.2012.01806.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

Review 1.  Molecular and nonmolecular diagnostic methods for invasive fungal infections.

Authors:  Marios Arvanitis; Theodora Anagnostou; Beth Burgwyn Fuchs; Angela M Caliendo; Eleftherios Mylonakis
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis.

Authors:  Mojtaba Taghizadeh-Armaki; Mohammad T Hedayati; Vahid Moqarabzadeh; Saham Ansari; Saeed Mahdavi Omran; Hossein Zarrinfar; Sasan Saber; Paul E Verweij; David W Denning; Seyedmojtaba Seyedmousavi
Journal:  J Med Microbiol       Date:  2017-07-12       Impact factor: 2.472

3.  Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis.

Authors:  M Hoenigl; J Prattes; B Spiess; J Wagner; F Prueller; R B Raggam; V Posch; W Duettmann; K Hoenigl; A Wölfler; C Koidl; W Buzina; M Reinwald; C R Thornton; R Krause; D Buchheidt
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

Review 4.  Aspergillus fumigatus and Aspergillosis in 2019.

Authors:  Jean-Paul Latgé; Georgios Chamilos
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

5.  Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive Aspergillosis enhances diagnostic capabilities.

Authors:  M Reinwald; B Spiess; W J Heinz; C P Heussel; H Bertz; O A Cornely; J Hahn; T Lehrnbecher; M Kiehl; H J Laws; H H Wolf; R Schwerdtfeger; B Schultheis; A Burchardt; M Klein; M Dürken; B Claus; F Schlegel; M Hummel; W-K Hofmann; D Buchheidt
Journal:  J Clin Microbiol       Date:  2013-10-09       Impact factor: 5.948

Review 6.  Current challenges in the microbiological diagnosis of invasive aspergillosis.

Authors:  Jesús Guinea; Emilio Bouza
Journal:  Mycopathologia       Date:  2014-06-20       Impact factor: 2.574

7.  Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients.

Authors:  Koen de Heer; Marije G Gerritsen; Caroline E Visser; Mariska Mg Leeflang
Journal:  Cochrane Database Syst Rev       Date:  2019-05-20

8.  Invasive Aspergillus infections in hospitalized patients with chronic lung disease.

Authors:  Mireya Wessolossky; Verna L Welch; Ajanta Sen; Tara M Babu; David R Luke
Journal:  Infect Drug Resist       Date:  2013-05-27       Impact factor: 4.003

9.  Aspergillus-PCR in bronchoalveolar lavage for detection of invasive pulmonary aspergillosis in immunocompromised patients.

Authors:  Michael Buess; Gieri Cathomas; Jörg Halter; Lilian Junker; Peter Grendelmeier; Michael Tamm; Daiana Stolz
Journal:  BMC Infect Dis       Date:  2012-10-02       Impact factor: 3.090

10.  Advancing the Field: Evidence for New Management Strategies in Invasive Fungal Infections.

Authors:  C Orla Morrissey
Journal:  Curr Fungal Infect Rep       Date:  2013-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.